UBS Global Life Sciences Conference
|
|
- Jocelyn Boyd
- 6 years ago
- Views:
Transcription
1 September 21, 2010 UBS Global Life Sciences Conference Tecan Group AG Thomas Bachmann, CEO
2 September 21, 2010 / p2 / UBS Global Life Sciences Conference Introducing Tecan Provider of instruments and workflow-solutions to the world s pharma, biotech, diagnostic and forensic laboratories and companies Our solutions accelerate, automate and enhance the processes in stateof-the-art life sciences laboratories Global leader in laboratory automation for 30 years Leading provider of OEM instruments and components HQ in Switzerland, 3 manufacturing and R&D sites; >1,100 employees; maintaining a sales and service network in 52 countries Listed at the SIX Swiss Exchange (TECN; TECN SW)
3 September 21, 2010 / p3 / UBS Global Life Sciences Conference Tecan s Markets, Customers, Applications Life Science Research Forensics Diagnostics Total size: 37bn USD Lab autom.: 2.5bn USD LT growth: 3% - 5% Total size: 1.3bn USD Automation: 470m USD LT growth: 15% Total size: 38bn USD Automation: 6bn USD LT growth: 5% - 7% Customers Pharmaceutical Companies Biotech Companies Academia CROs Government Institutions Research - Genomics - Proteomics - Cell-based Drug Discovery Production of proteins and cells Law Enforcement Agencies Government Laboratories Blood Banks Reference Laboratories Hospitals Diagnostics Companies (OEM) Applications Human Identification with DNA samples found at crime scenes, disaster sites etc. Proof of relationships Screening of populations or particular groups Blood typing Testing against diseases Pre- & post natal screening Personalized medicine and companion diagnostics
4 September 21, 2010 / p4 / UBS Global Life Sciences Conference New Group Organization Components & Detection Liquid Handling & Robotics sold/discontinued Sample Management Old product segmentation New customer segmentation Life Sciences Business Focused on all end-customer activities Partnering Business Focused on all OEM activities Development & Supply Operations Science & Technology
5 September 21, 2010 / p5 / UBS Global Life Sciences Conference Applications & Integrated Workflow Solutions Software Service Consumables Life Sciences Business User Interfaces Modules Instruments Quality & Regulatory Reagents 3rd Party Devices
6 September 21, 2010 / p6 / UBS Global Life Sciences Conference Various Co-Operation Models and Many Applications Life Sciences Business Numerous partnerships with global and local reagent and assay providers Tecan provides a number of innovative, off-the-shelf solutions that are specifically tailored for applications in the life sciences and diagnostics fields Tecan provides numerous sample preparation front-end solutions for widely used analyzers Increasing regulatory requirements demand for validated solutions Standardized workflow solutions gain in importance in all markets
7 September 21, 2010 / p7 / UBS Global Life Sciences Conference OEM Business Opportunity Partnering Business Today majority of OEM market is captive, i.e. instruments developed by IVD & LSR companies Trend towards outsourcing Focus on faster time to market, cost and existing service network OEM sales Components Instruments, Services & Consumables End-user Market ~$ 1.2bn* today ~$ 1.5bn* in 5 years OEM Market ~$ 6bn* ~10%* today OEM as a % of total sales OEM Business 27.7% 30.8% End-user Business ~$ 8bn* ~20%* in 5 years captive open *Tecan estimates 44.2% CHF (mio) H Total sales for all periods are from continuing operations only H1 2010
8 September 21, 2010 / p8 / UBS Global Life Sciences Conference Tecan s Broad OEM Offering Integrated Solutions Concepts developed by Tecan and showcased to potential partners Integrating instrument, plastic consumables and enabling reagents Partnering Business Customer Service & Spare Parts Dedicated Solutions Platform-based Solutions OEM Components Plastic Consumables
9 September 21, 2010 / p9 / UBS Global Life Sciences Conference Strategic Growth Driver: Services & Consumables Services & Consumables sales S&C as a % of total sales Life Sciences Business CHF (mio) Services Consumables Services & Consumables Instruments 29% 31% 32% H H Total sales for all periods are from continuing operations only Partnering Business Examples for sales per year: Diagnostics: CHF 15K (e.g. EVOlyzer, M2000) Forensics: CHF 20K (e.g. HID EVOlution) Life Science Research: CHF 50K (MCA 384 for high-throughput screening) Development of application-specific, patentable consumables underway Individual process or analytical steps taking place directly within consumable itself
10 September 21, 2010 / p10 / UBS Global Life Sciences Conference Strategic Growth Driver: Global Business Focus Life Sciences Business Partnering Business Major investments in public healthcare and life science research in emerging markets Recent global market development for Tecan end-user business: Asia Pacific HQ in Shanghai opened in October 2008; continued investments in infrastructure and market organization Project Ginseng in concept phase: defining growth case with new emerging markets products; building cost case for existing products to lower COGS Tecan implant with distributor to regain momentum in Australasia; potential to expand model to other markets Further growth opportunities in emerging markets through OEM partners Americas Europe, Near & Middle East, Africa Greater Asia
11 September 21, 2010 / p11 / UBS Global Life Sciences Conference H Strong Business Performance Significant sales growth in H1 2010: +9.1% in CHF and +12.2% in LC EBIT increased by 11.0% with EBIT margin of 13.0% (H1 2009: 12.8%) Global OEM business grew by 52.4%; now contributing 44% to total sales Strong performance in Services and Consumables (Consumables only: +17.5%); 32% of total sales Order entry increased by 7.4% in CHF and 10.7% in LC Strong cash flow from operating activities (11.7% of sales) Results from continuing operations only
12 September 21, 2010 / p12 / UBS Global Life Sciences Conference 2010 Outlook for Continuing Operations Sales guidance FY 2010 Sales growth above market average expected Aiming for growth between 6-8% in local currency terms EBIT Margin guidance FY % (including additional investments of up to CHF 3 million) Corresponding to % in 2009 constant currencies
13 Safe Harbor Statement All statements in this presentation not referring to historical facts are predictions of the future and constitute no guarantee whatsoever of future performances. They are subject to risks and uncertainties including, but not limited to, future global economic conditions, exchange rates, legal regulations, market conditions, activities of competitors and other factors outside the Company s control. Tecan Group AG is making all efforts to include accurate and up-to-date information into this presentation. Yet, it cannot be ruled out that omissions or errors might have occurred. Therefore, Tecan Group AG cannot make any representations or warranties, expressed or implied, as to the accuracy or completeness of the information provided in this presentation. Changes in this presentation can be made any time without notice. All mentioned trademarks are protected by law. Tecan Group AG, Tecan Trading AG, Switzerland, all rights reserved.
UBS Global Life Sciences Conference
September 20, 2011 UBS Global Life Sciences Conference Tecan Group AG Dr. Rudolf Eugster, CFO September 20, 2011 / p2 / UBS GLSC Contents Introducing Tecan Strategic Growth Drivers Financials H1 2011 &
More informationTecan Group 34 th Annual J.P. Morgan Healthcare Conference DR. DAVID MARTYR, CEO JANUARY 14, 2016 SAN FRANCISCO, USA
Tecan Group 34 th Annual J.P. Morgan Healthcare Conference DR. DAVID MARTYR, CEO JANUARY 14, 2016 SAN FRANCISCO, USA Safe Habor Statement All statements in this presentation not referring to historical
More information2009 INVESTOR DAY. BioPharmaceuticals. Ken Frank President BioPharmaceuticals December 17, Sustainable, Profitable Growth
2009 INVESTOR DAY BioPharmaceuticals Ken Frank President BioPharmaceuticals December 17, 2009 Sustainable, Profitable Growth Life Sciences FY 2009 Total Sales $2,329.2 (amounts shown in millions) BioPharmaceuticals
More informationPerkinElmer, Inc. JP Morgan Global Healthcare Conference. Robert Friel, Chairman and CEO January 14, 2015 HUMAN HEALTH ENVIRONMENTAL HEALTH
PerkinElmer, Inc JP Morgan Global Healthcare Conference Robert Friel, Chairman and CEO January 14, 2015 HUMAN HEALTH ENVIRONMENTAL HEALTH 2014 PerkinElmer FACTORS AFFECTING FUTURE PERFORMANCE & NON-GAAP
More informationInvestor Overview Presentation ADVANCING LIFE SCIENCE TOGETHER
Investor Overview Presentation ADVANCING LIFE SCIENCE TOGETHER Forward-Looking Statement Disclaimer In order to take advantage of the safe harbor provisions of the private securities litigation reform
More informationAgilent Technologies First Quarter Fiscal 2017 Conference Call Prepared Remarks
Agilent Technologies First Quarter Fiscal 2017 Conference Call Prepared Remarks ALICIA RODRIGUEZ Thank you, and welcome everyone to Agilent's First Quarter Conference Call for Fiscal Year 2017. With me
More informationJ.P. MORGAN Healthcare Conference Robert Friel Chairman and CEO January 10, 2018
J.P. MORGAN Healthcare Conference Robert Friel Chairman and CEO January 10, 2018 Factors affecting future performance & non-gaap financial measures This presentation contains "forward-looking" statements
More informationForward looking statements
Update on QIAensemble strategy May 8, 2011-1 - Sample & Assay Technologies Forward looking statements Safe Harbor Statement: Certain of the statements contained in this presentation may be considered forwardlooking
More informationTe-Options TWO INSTRUMENTS, UNLIMITED OPTIONS, INDIVIDUAL SOLUTIONS.
Te-Options TWO INSTRUMENTS, UNLIMITED OPTIONS, INDIVIDUAL SOLUTIONS. 02 Flexible options to meet changing needs For Freedom EVO and Fluent TeVacS high throughput vacuum separation The Te-VacS is an automated
More informationQIAGEN Sample & Assay Technologies From Discovery to Patient
QIAGEN From Discovery to Patient New York, February 14 QIAGEN 2008 Analyst & Investor Day Peer Schatz, CEO -7- Forward Looking Statements Safe Harbor Statement: Certain of the statements contained in this
More informationJP Morgan. Global Healthcare Conference. Robert Friel, Chairman and CEO January 11, PerkinElmer
JP Morgan Global Healthcare Conference Robert Friel, Chairman and CEO January 11, 2017 2016 PerkinElmer Factors affecting future performance & non-gaap financial measures This presentation contains "forward-looking"
More informationJP Morgan Global Healthcare Conference
JP Morgan Global Healthcare Conference January 12, 2016 Robert Friel, Chairman and CEO Factors affecting future performance & non-gaap financial measures This presentation contains "forward-looking" statements
More informationMARKETS & CUSTOMERS. Progressing globalization. Evolving markets
Peptides are used worldwide in medical research. They contribute immensely to the understanding of diseases and have proven to be effective in medicinal products. Today, peptides can be produced at low
More informationGENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE)
TriMark Publications April 2007 Volume: TMRGER07-0401 GENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE) Trends, Industry Participants, Product Overviews and Market Drivers TABLE OF CONTENTS
More informationPerkinElmer, Inc. Andy Wilson, CFO May 13, 2015 HUMAN HEALTH ENVIRONMENTAL HEALTH. Bank of America Merrill Lynch Global Healthcare Conference
PerkinElmer, Inc Bank of America Merrill Lynch Global Healthcare Conference Andy Wilson, CFO May 13, 2015 HUMAN HEALTH ENVIRONMENTAL HEALTH 2014 PerkinElmer FACTORS AFFECTING FUTURE PERFORMANCE & NON-GAAP
More informationPAREXEL GENOMIC MEDICINE SERVICES. Applying genomics to enhance your drug development journey
PAREXEL GENOMIC MEDICINE SERVICES Applying genomics to enhance your drug development journey YOUR JOURNEY. OUR MISSION. Genomic expertise to simplify the route to product approval and maximize patient
More informationINVESTOR PRESENTATION
INVESTOR PRESENTATION SWISS EQUITIES CONFERENCE BAADER HELVEA R. ERNI, CFO BAD RAGAZ 12 JANUARY 2018 Panalpina Biz Model / Strategy Achievements and key figures Operating and financial review Appendix
More informationIMMUNOASSAY MARKET. Global Forecast to MarketsandMarkets
IMMUNOASSAY MARKET [Technology (Enzyme, Fluorescent, Chemiluminescence, Radioimmunoassay), Analyzers & Reagents, Application (Infectious Diseases, Cancer, Endocrinology, Cardiology), End-Users (Hospitals,
More informationMargins of pharmaceutical companies are continuing to decline the future lies in new ecosystems
Karin Mateu Media Relations Tel.: +41 (0) 58 286 44 09 karin.mateu@ch.ey.com Margins of pharmaceutical companies are continuing to decline the future lies in new ecosystems Glaxo is leading the way in
More informationPresentation for Deutsche Bank Swiss Equities Conference
Zurich Airport, 19 th May 2010 Monika Ribar, CEO Presentation for Deutsche Bank Swiss Equities Conference 19 th May 2010 2 Panalpina at a glance Comprehensive global network Among top 5 globally in air
More informationBringing custom solutions and contract manufacturing to life
GE Healthcare Bringing custom solutions and contract manufacturing to life Imagined. Delivered. Supported. Custom and bulk solutions Tailored to your precise specifications, our custom products deliver
More informationOTC Virtual Investor Conference
OTC Virtual Investor Conference October 4, 2018 Dr. Chris L. Coccio Chairman and CEO Stephen Harshbarger President 2018 Sono Tek Corporation Safe Harbor Statement This presentation contains forward-looking
More informationAKESOgen, Inc, 3155 Northwoods Place, NW, Norcross, GA 30071, USA Tel: +1 (770) Page 1
Page 1 HLA Sequencing Based Typing Workflow: A- Sample Collection: iswab-discovery (Mawi DNA Technologies) - Sample was transported by standard US postal services mail, no cold chain of any sort was involved
More informationTecan based solutions for clinical microbiology labs ID/AST Workflow Automation
Tecan based solutions for clinical microbiology labs ID/AST Workflow Automation Main workflow in clinical microbiology lab Maldi-TOF ID Human samples. e.g. Urine Blood e-swabs Streaking Incubation Colonies
More informationMolecular Diagnostics at the Point of Need Interim Results (to Dec-17) 20 March 2018
Molecular Diagnostics at the Point of Need Interim Results (to Dec-17) 20 March 2018 2 Decentralising molecular diagnostics DOCUMENT INFORMATION The information contained in this document and made verbally
More informationBio-Analytical Measurement Business Briefing
Bio-Analytical Measurement Business Briefing 58 th Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy McCormick Place Chicago, Illinois February 26, 2007 Page 1 Safe-Harbor Statement
More informationAdept Technology Investor Presentation March 2015
Adept Technology Investor Presentation March 2015 Safe Harbor This presentation includes forward-looking statements, including statements about the economic environment affecting us and the markets we
More information37 th Annual JP Morgan Healthcare Conference
37 th Annual JP Morgan Healthcare Conference Todd M. Pope, President & CEO January 7, 2019 FORWARD LOOKING STATEMENTS This presentation includes statements relating to the Senhance Surgical System and
More information34 th Annual J.P. Morgan Healthcare Conference
34 th Annual J.P. Morgan Healthcare Conference Vincent A. Forlenza Chairman, Chief Executive Officer and President January 13, 2016 Forward-Looking Statements These materials include forward-looking statements
More informationHematology is in our blood
Hematology is in our blood Boule Diagnostics AB Nordea MedTech/Life Science Seminar November 27, 2018 Fredrik Dalborg, CEO and Group President Christina Rubenhag, CFO 2018-11-27 BOULE DIAGNOSTICS (1) Copyright
More informationPersonalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies
Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies The value of In Vitro Diagnostics The value of diagnostics as an integral part in the healthcare value chain Diagnostics
More informationInvestor Presentation
Investor Presentation Michael Willome, Group CEO Baader Helvea Swiss Equities Conference Content Group overview & priorities Page 3 Segment performance, sales trend & outlook Page 10 Appendix: Leadership
More informationFY2017 to FY2019 Medium-Term Management Plan. March 29, 2017 Shimadzu Corporation President and CEO Teruhisa Ueda
FY2017 to FY2019 Medium-Term Management Plan March 29, 2017 Shimadzu Corporation President and CEO Teruhisa Ueda Contents I. Review of the Previous Plan p.1-4 II. Overview of the New Medium-Term Management
More informationEconomic Growth through Research & Innovation: The Greek Pharma Case
Economic Growth through Research & Innovation: The Greek Pharma Case Vassilios Katsos President & CEO, PHARMATHEN SA Vice President of Panhellenic Union of Pharmaceutical Industry 23 rd of April, 2015
More information2009 INVESTOR DAY. Medical. Allan Ross President Medical December 17, 2009
2009 INVESTOR DAY Medical Allan Ross President Medical December 17, 2009 Pall Life Sciences - Medical BioPharmaceuticals Medical 24% 17% 38% Energy, Water & Process Technologies 9% 12% Microelectronics
More informationSIKA CAPITAL MARKETS DAY FROM PATENTS TO WORLD CLASS PRODUCTS PAUL SCHULER, CEO, ZURICH, SEPTEMBER 20, 2017
SIKA CAPITAL MARKETS DAY FROM PATENTS TO WORLD CLASS PRODUCTS PAUL SCHULER, CEO, ZURICH, SEPTEMBER 20, 2017 TABLE OF CONTENTS 1. STRATEGIC TARGETS 2020 2. OUTLOOK 3. SUCCESSFUL STRATEGY EXECUTION LIFE-CYCLE
More informationAutomating the Bioprocessing Workflow
24 September 2014 Automating the Bioprocessing Workflow Daniel Leach Senior Application Scientist Biotherapeutic Workflow Design of Experiment Generate Experimental Conditions & Experimental Design Execute
More informationMultiplex Solution for Better Health
Multiplex Solution for Better Health About Us About Us Core Technology Technology s Precision Image Code () MicroDisc is manufactured by using a photo lithography fabrication process. This semi-conductor
More informationPathHunter β-arrestin Human and Ortholog GPCR Assays
PathHunter β-arrestin Human and Ortholog GPCR Assays Easy automation for cell-based assays on the Fluent laboratory automation solution Introduction The ability to carry out cell-based G-Protein coupled
More informationAgilent Technologies. Q4'18 Results Presentation
Agilent Technologies Q4'18 Results Presentation Safe Harbor This presentation contains forward-looking statements (including, without limitation, information and future guidance on the company s goals,
More informationDeutsche Bank German, Swiss & Austrian Conference
Deutsche Bank German, Swiss & Austrian Conference Arnd Zinnhardt CFO May 14, 2013 Safe-Harbor-Statement This presentation contains forward-looking statements based on beliefs of Software AG management.
More informationICON plc Brendan Brennan CFO
ICON plc Brendan Brennan CFO Jefferies HealthCare Conference New York 6 TH June 2017 Forward Looking Statement Certain statements will be forward looking statements. Actual results may differ materially
More informationWipro Limited. September - December Presentation to Investors 2016 WIPRO LTD
Wipro Limited September - December 2016 Presentation to Investors 1 Safe Harbor This presentation may contain certain forward looking statements, which involve a number of risks, uncertainties and other
More informationAutomation In Life Sciences and Diagnostics Applications
Automation In Life Sciences and Diagnostics Applications Pedro Diaz Director of Research Beckman Coulter Life Sciences February 20-22, 2013 Orlando World Marriott Center Orlando, Florida USA Beckman Coulter
More informationJefferies 2014 Global Healthcare Conference June 3, 2014 NYSE: Q
Jefferies 2014 Global Healthcare Conference June 3, 2014 NYSE: Q Copyright 2013 Quintiles Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements
More informationAnnual Media Conference Welcome
Annual Media Conference 2017 Welcome Agenda 9 March 2017 Financial Review, CFO Business Review, CEO Customer Presentation, UK Customer Presentation, Italy Guidance, CEO Q&A Product Demonstration Annual
More informationAdvances with Acoustics
Advances with Acoustics Evolution of Acoustic Dispensing and Next Generation Developments SLAS Europe Compound Management March 14, 2017 2016 LABCYTE INC. All rights reserved. Labcyte, Echo, the Labcyte
More informationNokia Siemens Networks Integration & restructuring update. Eric A. Simonsen Chief Financial Officer
Nokia Siemens Networks Integration & restructuring update Eric A. Simonsen Chief Financial Officer 1 Nokia Siemens Networks Capital Markets Day 2007 Key quarterly figures in 2007 Geographic distribution
More informationAgilent Technologies Third Quarter Fiscal 2018 Conference Call Prepared Remarks
Agilent Technologies Third Quarter Fiscal 2018 Conference Call Prepared Remarks ALICIA RODRIGUEZ Thank you, and welcome everyone to Agilent's Third Quarter Conference Call for Fiscal Year 2018. With me
More informationInnovative Medicines Initiative
Innovative Medicines Initiative EMA - EBE Regulatory Conference on ATMPs Salah-Dine Chibout, Novartis Global Head Discovery & Investigative Safety/ Global Head Preclinical Safety Therapeutic Areas IMI
More informationFull year 2014 results
Listen-only live audio webcast available from www.gemalto.com/investors Full year 2014 results March 5, 2015 Olivier Piou, CEO Jacques Tierny, CFO Disclaimer This communication does not constitute an offer
More informationFreedom EVOlyzer Tailor your platform for fully automated ELISA processing
Freedom EVOlyzer Tailor your platform for fully automated ELISA processing Freedom EVOlyzer the powerful ELISA analyzer The Freedom EVOlyzer is a dedicated platform for automating microplate-based ELISAs,
More informationLabcyte Overview. Mark Fischer-Colbrie
MOVING LIQUIDS with SOUND Labcyte Overview Mark Fischer-Colbrie 2016 LABCYTE INC. All rights reserved. Labcyte, Echo, the Labcyte logo are registered trademarks or trademarks of Labcyte Inc., in the U.S.
More informationDIGITAL PATHOLOGY: TECHNOLOGIES AND GLOBAL MARKETS
DIGITAL PATHOLOGY: TECHNOLOGIES AND GLOBAL MARKETS HLC161A February 2014 Bhavna Joshi Project Analyst ISBN: 1-56965-706-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationThermo Scientific ARM Automation Platform
Thermo Scientific ARM Automation Platform Superior dexterity and proven robotics come together on one platform to automate the most challenging drug discovery applications. The Trusted Choice to Automate
More informationAnnual Stockholder Meeting
Annual Stockholder Meeting Jeff Henley Oracle Vice Chairman November 16, 2016 Copyright 2016, Oracle and/or its affiliates. All rights reserved. Safe Harbor Statement Statements in this presentation relating
More informationInvestor presentation Responsible growth. Shared success.
Investor presentation Responsible growth. Shared success. Givaudan products drive millions of consumer decisions every day! Key drivers of consumer repurchase decisions The fragrance and flavour industry
More informationWipro Limited. April - June Presentation to Investors 2017 WIPRO LTD
Wipro Limited April - June 2017 Presentation to Investors 1 Safe Harbor This presentation may contain certain forward looking statements, which involve a number of risks, uncertainties and other factors
More informationBASF signs agreement to acquire significant parts of Bayer s seed and non-selective herbicide businesses. October 13, 2017
BASF signs agreement to acquire significant parts of Bayer s seed and non-selective herbicide businesses October 13, 2017 Cautionary note regarding forward-looking statements This presentation contains
More informationICON plc. 10th Jan Ciaran Murray CEO Steve Cutler CEO Designate. JP Morgan 35TH Annual Healthcare
ICON plc Ciaran Murray CEO Steve Cutler CEO Designate JP Morgan 35TH Annual Healthcare 10th Jan 2017 Forward Looking Statement Certain statements will be forward looking statements. Actual results may
More informationAutomotive Aftermarket 2025
Automotive Aftermarket CLEPA Conference March 22nd, 2018 THE GLOBAL AFTERMARKET Global AM parts retail market value by region bn EUR 38 +5.7% 59 135 +3.2% 174 85 +2.3% 102 86 +8.6% 166 Global +4.5% 44
More informationBiotechnology Certificate New Technologies For Health
Weekly Barometer 25 janvier 2012 Biotechnology Certificate New Technologies For Health April 2017 ATONRÂ PARTNERS SA 12, Rue Pierre Fatio 1204 GENEVA SWITZERLAND - Tel: + 41 22 310 15 01 http://www.atonra.ch
More informationCommerzbank Sector Conference - Technology, Media & Telecoms -
Commerzbank Sector Conference - Technology, Media & Telecoms - August 29, 2012 Arnd Zinnhardt, CFO August 29, 2012 2 Safe-Harbor-Statement This presentation contains forward-looking statements based on
More informationMr. Lou Panaccio Executive Chairman
Mr. Lou Panaccio Executive Chairman 1 Overview Objective Develop compelling multiplexed test solutions for the $4BN global molecular diagnostic testing industry using our silica bead based AmpaSand technology
More informationMolecular Diagnostics
Molecular Diagnostics Part II: Regulations, Markets & Companies By Prof. K. K. Jain MD, FRACS, FFPM Jain PharmaBiotech Basel, Switzerland May 2018 A Jain PharmaBiotech Report A U T H O R ' S B I O G R
More informationBiotechnology Certificate New Technologies For Health
Weekly Barometer 25 janvier 2012 Biotechnology Certificate New Technologies For Health January 2018 ATONRÂ PARTNERS SA 12, Rue Pierre Fatio 1204 GENEVA SWITZERLAND - Tel: + 41 22 310 15 01 http://www.atonra.ch
More informationInvestor presentation: July October 2018 Responsible growth. Shared success.
Investor presentation: July October 2018 Responsible growth. Shared success. Givaudan products drive millions of consumer decisions every day! F&F: the key driver of consumer repurchase decisions Critical
More informationA fluorogenic assay for identification of coagulation factor IIa inhibitors- screening for stroke treatment
A fluorogenic assay for identification of coagulation factor IIa inhibitors- screening for stroke treatment Easy automation of a biochemical assay on the Fluent laboratory automation solution Introduction
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION March 2018 1 Forward Looking Statement This presentation includes statements relating to the company's Acuitas MDRO and Acuitas Lighthouse clinical laboratory services, FDA cleared
More informationBD Strategy Overview. Advancing the world of health. Vincent A. Forlenza Chairman, Chief Executive Officer and President
BD Strategy Overview Advancing the world of health Vincent A. Forlenza Chairman, Chief Executive Officer and President BD IS AT THE VERY BEGINNING OF AN AMAZING JOURNEY WHERE WE CAN HAVE A PROFOUND IMPACT
More informationAnnual Meeting of Shareholders
Annual Meeting of Shareholders Edward J. Ludwig Chairman and Chief Executive Officer February 3, 2009 Agenda Corporate Strategy Performance Trends Growth Drivers 2 Corporate Strategy Drive Revenue Growth
More informationA LEADING TECH COMPANY. March 2013
A LEADING TECH COMPANY March 2013 This document contains statements including forward looking statements regarding future performance of the Company. Analyst and investors must be aware that such statements
More informationStart With the End in Mind A Diagnostic Company s Perspective on Companion Diagnostic Development. Paul Docherty PhD Relationship Management
Start With the End in Mind A Diagnostic Company s Perspective on Companion Diagnostic Development Paul Docherty PhD Relationship Management Disclaimer This presentation contains my personal views and research
More informationSoftware AG Heading for Growth
Software AG Heading for Growth Karl-Heinz Streibich, CEO June 01, 2006 Credit Suisse European Technology Conference, Barcelona, Spain This presentation contains forward-looking statements based on beliefs
More informationBio-Pharma: China A Look at The FUTURE: 4 th & 5 th Generation Global Strategies
Global Strategy Global Challenges Executable Solutions Bio-Pharma: China 2010-2020 A Look at The FUTURE: 4 th & 5 th Generation Global Strategies France Houdard Managing Director January 2010 Table of
More informationMolecular Diagnostics at the Point of Need
Molecular Diagnostics at the Point of Need 24 November 2016 David Budd CEO d.budd@genedrive.com 1 DOCUMENT INFORMATION The information contained in this document and made verbally to you (together the
More informationImpact of Standardizing on Traceable QC for Volume Transfers Artel
Impact of Standardizing on Traceable QC for Volume Transfers 1 The challenges How is liquid handler performance evaluated in your lab? What information do you obtain (accuracy and/or precision)? How long
More informationAgilent Technologies Fourth Quarter Fiscal 2017 Conference Call Prepared Remarks
Agilent Technologies Fourth Quarter Fiscal 2017 Conference Call Prepared Remarks ALICIA RODRIGUEZ Thank you, and welcome everyone to Agilent's Fourth Quarter Conference Call for Fiscal Year 2017. With
More informationMORGAN STANLEY LAGUNA CONFERENCE Dan Comas September 15, 2016
MORGAN STANLEY LAGUNA CONFERENCE Dan Comas September 15, 2016 Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding events or developments
More informationLogitech. July 25, 2012
Logitech Q1 Fiscal Year 2013 July 25, 2012 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. federal securities laws, including, without limitation,
More informationDedicated to Molecular Diagnostics
Dedicated to Molecular Diagnostics For Europe Sample & Assay Technologies QIAGEN s growing role in molecular diagnostics At QIAGEN, one of our key goals is to support clinical decision-making and improve
More informationNapatech. Q Presentation August 14, Napatech A/S Copyright 2018
Napatech Q2 2018 Presentation August 14, 2018 1 Napatech A/S Copyright 2018 Highlights Sales performance for Q2 2018 53% decrease in USD Sales for Q2 2018 56% decrease in DKK Revenue for Q2 2018, 11% increase
More informationA good diagnosis is half the cure
Investor Dagen Dansk Aktionærforening BioPorto A/S, June 13, 2017 A good diagnosis is half the cure Forward looking statements This presentation contains forward-looking statements. Words such as believe,
More informationPolicies that encourage innovation in middle-income countries
December 2012 Policies that encourage innovation in middle-income countries The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) asked Charles River Associates (CRA) to
More informationBaader Swiss Equities Conference 12 January 2018, Bad Ragaz. Reto Welte, CFO Dätwyler Group
Baader Swiss Equities Conference 12 January 2018, Bad Ragaz Reto Welte, CFO Dätwyler Group Datwyler Group Highlights Focused industrial supplier with global presence Leading positions in global and regional
More informationLogitech. July 24, 2013
Logitech Q1 Fiscal Year 2014 July 24, 2013 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the federal securities laws, including, without limitation,
More informationTAIWAN. Who Should Attend? Endless Potential & Opportunities. Where innovations are shaping a new era of intelligent healthcare.
TAIWAN Where innovations are shaping a new era of intelligent healthcare World-class medical centers and hospitals Over 1800 biotech companies Best healthcare system in the world Top-ranked life science
More informationTECAN AT A GLANCE. Seizing opportunities in Life Sciences
TECAN AT A GLANCE «Seizing opportunities in Life Sciences» Tecan Seizing opportunities in Life Sciences Tecan vs. SPI in CHF 22 18 16 14 12 1 8 6 4 Tecan is a leading player in the fast growing Life Sciences
More informationTerritory Account Manager (MD, NC or TX based)
Territory Account Manager (MD, NC or TX based) Looking for bilingual Chinese-English young professionals with passion in selling genomics services. The Territory Account Manager's role is to ensure achievement
More informationDNA Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast,
DNA Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013-2019 The completion of human genome project resulted in discovery of several human disease causing genes.
More informationHCL TECHNOLOGIES EARNINGS PRESENTATION SECOND QUARTER FY 16 WHERE VALUES DRIVE VELOCITY
HCL TECHNOLOGIES EARNINGS PRESENTATION SECOND QUARTER FY 16-1 - Performance Snapshot ANANT GUPTA - 2 - In USD Mn Number Of Clients In USD Mn In USD Mn PERFORMANCE TRENDS (CALENDAR YEAR BASIS) REVENUE EBIT
More informationGlobal In-Vitro Diagnostic Market Report
Global In-Vitro Diagnostic Market Report ----------------------------------------------------- 2013 Executive Summary The process of performing a diagnostic test outside of a living organism in an artificial
More informationFebruary 25, 2019 (Monday) 8:30-16:30 Hrs BioPark Visit (Only for Invitees)
February 25, 2019 (Monday) 8:30-16:30 Hrs BioPark Visit (Only for Invitees) 18:00-19:30 Hrs Inauguration of the 16 th BioAsia Convention Presentation of Genome Valley Excellence Award 19:30-20:00 Hrs Inauguration
More informationBTS Group AB (publ) 2011 General Annual Meeting. Stockholm, Thursday May 5, Henrik Ekelund President & CEO
BTS Group AB (publ) 2011 General Annual Meeting Stockholm, Thursday May 5, 2011 Henrik Ekelund President & CEO When training really has to work! Commercial Flight Simulator Advanced Surgical Simulator
More informationHenkel. 17 th German Corporate Conference Frankfurt, January 15, 2018
Henkel 17 th German Corporate Conference Frankfurt, Disclaimer This information contains forward-looking statements which are based on current estimates and assumptions made by the corporate management
More informationInvestor Presentation
Siemens Ltd., 2 www.siemens.co.in Disclaimer This presentation has been prepared solely for use at the investor/analyst presentation. By attending the meeting where this presentation is made, or by reading
More informationAccelrys ROTH Growth Stock Conference
Accelrys ROTH Growth Stock Conference Feb. 20, 2008 Presented by: Mark Emkjer, CEO Rick Russo, CFO Forward-looking Statements When used in this presentation, words such as expects, believes, anticipates,
More informationCRS Dimension4 Modular Automation Platform
CRS Dimension4 Modular Automation Platform Perform your most important applications on one fast, flexible system. Only Thermo s CRS Dimension4 automation platform brings together flexibility, modularity,
More informationT R O P E ANNUAL R 2012
2012 ANNUAL REPORT [ V I S I O N ] Breakthrough solutions to improve health and advance science. 2012 was a year of growth and investment for Luminex. We achieved record revenue driven by a 54% increase
More information